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Enzymes have often been used for immunological studies as antigens (1-4), 
and as reagents to tag either antigens (5, 6) or antibodies (7, 8), because of the 
ease, sensitivity, and specificity of enzyme assays.  Moreover, antibodies may 
affect  the  catalytic  properties  of  enzymes,  thereby  providing  a  convenient 
tool to measure the interaction of  the  two  molecules.  The  most  frequently 
observed type of interaction leads to inactivation of the enzyme (9, 10); how- 
ever, it has been recently reported that antibodies can cause an increase in the 
enzymatic activity. The activation is usually not more than 3- or 4-fold, with 
the exceptions of a  70-fold increase shown for the  peniciUinase  of  a  Bacillus 
subtilis mutant  (11)  and a  500-fold increase  for  a  genetically  defective /3-1)- 
galactosidase from Escherichia coli (12). 
The latter system seemed of interest  to us,  since, in  addition  to  the large 
activation factor,/3-1)-galactosidase is a well-studied enzyme offering two main 
advantages over other enzymes. Namely, it can be assayed at the single mole- 
cule level (13)  and its synthesis can be genetically controlled so as to obtain a 
series of polypeptides which are useful for the immunological characterization 
of  the  enzyme  (14),  since  they  range  from relatively small  polypeptides  to 
molecules differing from the normal enzyme by a  single amino acid  (15,  16). 
In the first paper of this series  (12)  we described the purification and bio- 
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chemical  characterization  of a  defective 3-D-galactosidase  (AMEF) 1 which  is 
activable  by specific antibodies  directed  against  the normal enzyme (Z).  The 
AMEF was extracted from a  point mutant  of E.  coli shown to have a  defect 
in  the  structural  gene  for  /~-galactosidase  (17).  The  sedimentation  rate  of 
AMEF  is  comparable  to that  of  the  tetramer  form of ~-galactosidase.  This, 
together with  studies  of specificity of induction,  indicated  that AMEF is  the 
product of an altered Z gene, probably differing from the wild-type enzyme by 
one amino acid. The major difference in the physical properties  of AMEF and 
Z is that the former is more electronegatively charged as shown by electrophore- 
sis in acrylamide gel (unpublished  results). 
The reaction of AMEF with the antibody is characterized by an increase in 
enzymatic activity directly proportional to the concentration of either antibody 
(12)  or Fab fragments  (18). The results of kinetics studies are consistent with 
the  postulate  that  activation  of AMEF results  from a  single hit  involving  a 
discrete  number  of  antigenic  determinants  (18).  Further  evidence  that  one 
molecule  of Fab  can  activate  one  molecule  of AMEF  has  been  obtained  by 
direct  measurements  of  single  molecules  of  the  AMEF-Fab  complex. 2  In 
addition,  the latter  studies  have shown that,  with some antisera,  the activity 
of the AMEF-Fab complex can reach a maximum value of about one-third of 
that of a normal Z molecule. 
Given  the properties  of the AMEF-antibody system as summarized  above, 
it follows that it could serve well as a prototype to study the protein-to-protein 
interactions  leading  to  conformational  and  functional  changes,  reactions  for 
which  there  is  increasing  interest  among biologists.  From  the  immunological 
point  of view,  the  binding  of an  activating  antibody molecule  to  the  corre- 
sponding antigenic  site  of AMEF  can be compared with  the  specific reaction 
of an  anti-hapten  immunoglobin  and  the  protein-bound  hapten.  Accordingly, 
this  system could be used to test  the general validity of the concepts derived 
from experimentation  with carrier-hapten  models by extending them to given 
determinants  of a native protein. As a first step in this direction, the immuno- 
genic and antigenic properties  of AMEF and Z  are described in this  article. 
Materials and Methods 
Diluents.--Buffer B contained  10 mM tris  (hydroxymethyl)  aminomethane  (Tris), 10 m~ 
MgC12, 0.1 ~ NaC1, and 0.05 M 2-mercaptoethanol and its pH was adjusted  to 7.05 (23°C) 
with acetic acid. The complete buffer was prepared daily by adding the mercaptoethanol  to 
1  Abbreviations  used in this paper: AMEF,  a genetically defective 3-D-galactosidase; EU, 
enzyme unit,  the amount of ~-D-galactosidase which hydrollzes 10  --9 mole of substrate/min; 
ONPG,  o-nitrophenyl-~-D-galaetopyranoside; P.U.,  the amount of serum necessary to pre- 
cipitate  1 EU of Z, taking 50% precipitation as the end point; s, galactosidase activity after 
centrifugation;  t, galactosidase activity before centrifugation; Z, normal/~-D-galactosidase of 
E. coll. 
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the stock salt solution. Whenever the buffer was used without mercaptoethanol, it is noted 
in the text. 
Chemicals.--Isopropyl-~-~-l-thiogalactopyranoside  and  o-nitrophenyl-/~-D-galactopyrano- 
side (ONPG) were purchased from Mann Research Labs. Inc., New York, Tris was obtained 
from Sigma Chemical Co., St. Louis, Me., and sodium lactate was from Fisher Scientific Com- 
pany, Pittsburgh, Pa. 
Bacterial  Strains  and  Conditions  of Culture.--A  /~-D-galactosidase  constitutive mutant of 
E. cell (3-300)  grown in tryptone4actate broth was used for the production of normal/3-D- 
galactosidase (19). For AMEF, either W6101 (F-, lacZ 201) or S 167  (F-, lacI, lacZ 201) was 
used. The former is an inducible strain, while the latter, a recombinant between W6101 and 
S 164 (HfrC, lacI), synthesizes AMEF constitutively (Ellis and Rotman, unpublished results). 
The bacteria were grown under aeration at 37°C  in minimal medium (20) containing 0.4% 
sodium lactate as sole carbon source. For induction,  5  X  10  -4 ~  isopropyl-/3-D-l-thiogalac- 
topyranoside was added to the growth medium. 
Assay of ~-94~alactosidase.--The enzymatic assay, identical for Z and AMEF, was done at 
37°C in a 2 ml volume of buffer B containing 3 mM ONPG. "[he reaction was stopped by adding 
either 3 ml of 0.2 ~  Na2CO3 or 0.5 ml of  1.2  M Na2CO3 and its optical density at 420 mtt 
was measured and converted to o-nitrophenol  concentration using a molar extinction coefficient 
(1 cm pathway) of 4700. An enzyme unit (EU) is defined as the amount of/3-9-galactosidase 
which hydrolizes 10  -9 mole of substrate/min under the above conditions. 
Purification of Z and AMEF.~--The procedures followed for the extraction of 3300, S167, 
and W6101 were similar.  Unless noted otherwise, all operations were done between 0  ° and 4°C. 
The bacteria were harvested at a density of about 109 cells/ml, washed three times with buffer 
B without mercaptoethanol, resuspended in the same buffer to a density of about 1012 cells/ml, 
and then disrupted in a French pressure cell [a MSA sonicator set at 1.4 amp for 4 min]. The 
resulting extract was freed of particulate matter by centrifuging first at 27,000 g for 15 rain 
in a Sorvall centrifuge (Ivan Sorvall,  Inc., Norwalk, Conn.) and then at 97,000 g for 60 rain 
in  a  Spinco model L  ultracentrifuge  (Spinco  Div.  Beckman Instruments Inc.,  Pale  Alto, 
Calif.). The supernatant was mixed with ~  of the volume of saturated ammonium sulphate 
(70.6 g dissolved in 100 ml of water and adjusted to pH 7.2 with 5 M NaOH)  and the pre- 
cipitate formed was removed by centrifugation at 27,000 g for 10 min. ~I'he supernatant was 
again mixed with saturated ammonium sulphate until 33%  [38%] saturation was reached. 
The mixture was allowed to stand for 20 rain at 0°C [1 hr at 4°C] and the precipitate obtained 
was spun down at 27,000 g for 10 rain, resuspended in a volume of 40% saturated ammonium 
sulphate equal to about three times that of the pellet, and stored at 4°C. Before experimental 
use, samples of the latter suspension were spun down and the pellet, after carefully removing 
the supernatant by a second brief centrifugation, was dissolved in buffer B and dialyzed for 
24  hr against the same buffer [passed  through a  Sephade× G-25  column  (Pharmacia Fine 
Chemicals Inc., Uppsala, Sweden)  (1.5 X  25 cm)] in order to eliminate the ammonium sul- 
phate. For some experiments where AMEF was used at such high dilution that the salt con- 
centrafion became negligible, the dialysis step was omitted. 
The activity of/3-D-galactosidase  solutions prepared by this procedure was stable for several 
weeks at 4°C, while the activity of AMEF preparations decayed considerably under the same 
conditions. Therefore, the latter was prepared daily as described above from stock suspensions 
under 40% ammonium sulphate. The protein concentrations of AMEF and Z solutions were 
standardized by measuring their optical density at 280 m#. For conversion to milligrams of 
protein per milliliter,  the optical density was multiplied by 0.5. 
3 Variations  in  procedures used  in  the  Stockholm  laboratory  are  indicated  in  square 
brackets. & 
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Quantitative  Assay of Immune Precipitation.--A given amount of Z, usually between 500 
and 1000 EU, in a volume of 0.3 ml, was added to each of a series of tubes containing 0.2 ml 
of progressive dilutions of the antiserum to be tested. The tubes were incubated 30 min at 
37°C [30 min at 37°C, then 60 min at 4°C], then centrifuged at 20,000 g for 10 min in a Clay 
Adams "micro-chemistry" centrifuge (Clay-Adams, Inc., Parsippany, N.Y.)  [at 48,000 g for 
20  rain in a  Sorvall  RC2B].  The supernatant of each of the tubes after centrifugation was 
assayed for ~-D-galactosidase  activity. Taking the activity before and after centrifugation as 
t and s, respectively, the fraction precipitated is expressed as 1 -- sit. The titer of a  serum 
is determined in slight antigen excess by taking the tube with highest dilution of antiserum, 
in which more than 50% of the Z is precipitated, as the end point. Under these conditions the 
number of enzyme units precipitated by 1/zl of undiluted serum is calculated by multiplying 
As V~ 
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Fro.  1.  Precipitation curve of Z  and  anti-Z made in  a  Technicon continuous analyzer. 
See Materials and Methods for details. 
the original number of enzyme units present in the tube by the fraction precipitated and by 
the serum dilution factor, and then dividing the result by 200  (the microliters of serum in 
the tube). 
For experiments involving a considerable number of ~-n-galactosidase assays, a Technicon 
continuous analyzer was used  (Technicon Co.,  Inc.,  Tarrytown,  N.Y.).  The  supernatants 
obtained before and after precipitation of the antibody-enzyme complex were placed in the 
analyzer and assayed at a rate of 20/hr. The instrument was run with the same solutions used 
in the manual method, except for the ONPG which was 10  -n M. A titration of an anti-Z serum 
in the Technicon is shown in Fig. 1. From the graph, one can evaluate both the titer of the 
antiserum and the profile of precipitation showing that the zones of antibody excess, equiva- 
lence, and antigen excess are well defineated. 
Assay  of Activation  of AMEF.--The  activating capacity of antisera was  measured by 
incubating 0.1  [0.05] ml of a  given dilution of the serum with 0.1  [0.05] ml of a  solution of 
AMEF containing about 100 #g protein/ml. After 30 rain at 37°C, a 0.1 [0.02] ml sample of the 
mixture was assayed for fl-D-galactosidase.  The activity of the tube containing the highest CELADA~ ELLIS~  BODLUND~ AND  ROTMAN  755 
dilution of  serum and showing a  significant difference above a  control with normal serum 
and AMEF was used for the calculation of the titer. For this, the increase in enzyme units 
elicited by  1 ml of diluted serum was multiplied by its dilution factor and the result was 
divided by 1000 to obtain the activation capacity of 1 #1 of serum. 
Animals and Immunization Procedures.--Male and female rabbits weighing between 2 and 
5 kg each were used. Immunization was done by injecting subcutaneously into the subscapular 
muscle 1 ml of either Z or AMEF solution containing from 3 to 20 mg protein emulsified with 
1 ml of complete Freund's adjuvant (Difco Laboratories, Detroit, Mich.). The same procedure 
was  repeated  for  secondary stimulation,  1 month after  the primary.  At varying intervals 
beginning 3 wk after primary stimulation and 1 wk after challenge bleedings were done by 
heart puncture or by cannulafing the central artery of the ear. The collected serum was kept 
at 4°C  after sterilization by filtration through Millipore  (Millipore Corp.,  Bedford,  Mass.) 
[at --30°C in small samples]. 
Male mice of the A. Sn strain, bred at the Department of Tumor Biology, were utilized at 
the age of 6-8 months, both for immunization experiments and as recipients in transfer ex- 
periments. The standard immunization dose of Z and AMEF was  100/zg/mouse, emulsified 
in Freund's adjuvant (Difco). A total volume of 0.2 ml of the emulsion was injected subcutane- 
ously into  the abdominal region.  To  elicit a  secondary response,  the same  procedure was 
repeated  1  month after  the primary  stimulation.  Bleeding of  the  injected mice was  done 
weekly  by puncturing the retro-orbital venous sinus and the sera obtained were stored in- 
dividually at --30°C until used. 
Adoptive Transfer Procedures.--Donor mice were killed by decapitation 2-3 months after 
immunization and their spleens were teased in ice-cold Eagle's tissue culture medium by using 
two miniature toothed forceps. The resulting suspension was passed several times through a 
syringe mounted with an 18-gauge needle and then filtered through a  stainless steel cloth of 
200 mesh/in, to eliminate cell clumps, washed, and adjusted to a concentration of l0  s cells/ml. 
A 0.2 ml sample of this suspension was given intravenously to each of the preirradiated re- 
cipient mice. Antigen challenge was given by injecting 0.2 ml of a solution of either Z or AMEF 
in buffer B containing 10/zg of protein. The recipients, usually eight per experimental group, 
were bled weekly after transfer. The irradiation conditions were as follows.  A  total dose of 
600 R was administered with a Philips machine (Philips Electronic Instrument, Mount Vernon, 
N.Y.)  set at 200 kvp,  15 ma. The inherent filter was 1 mm Al,  the added filter, 0.5 mm Cu. 
The animals were placed 50 cm from the source, in a  circular plexiglas container. A Philips 
integrating dosimeter was used; the dose rate was about 90 R/rain. 
RESULTS 
Difference Between Anti-Z and AnIi-AMEF Sera.--In contrast to Z, AMEF 
did not elicit  formation of antibodies capable of activating AMEF,  although 
the production of precipiting antibodies was  similar  to  that  of Z  (Table I). 
This  effect  was  observed  in  both  rabbits  and  mice.  By  the  criterion  of  the 
Ouchterlony  technique,  the cross-reaction between  the anti-Z and anti-AMEF 
sera  with  regard  to  the  two  antigens  is  complete  since  no  spurs  were  de- 
tected. 
Failure of Z  to Elicit  Antibodies in Animals  Presensitized with AMEF.--As 
shown  in  Table  II,  one  injection  of  AMEF  in  Freund's  adjuvant  altered  the 
immune  response of mice to subsequent  inoculation of Z  so that  no activiting 
antibodies were produced.  This suppressing effect of  AMEF  was  restricted  to 
activating  antibodies  as  shown  by  the fact  that  a  normal  secondary  response 756  ANTIBODY  ACTIVATION  OF  DEFECTIVE  ENZYME 
was observed  with  regard  to  precipitating  antibodies.  Identical  results  were 
obtained in rabbits, which were shown to remain incapable of responding with 
activating antibodies for prolonged  periods  of  time  (up  to  2  yr)  after  a  single 
injection of  1  5  mg of AMEF  in  Freund's  adjuvant. 
TABLE  I 
Precipitating and Activating Capacity of Anti-Z and Anti-A MEF Sera from Rabbits and Mice 
Titer 
Precipitation*  Activation+ 
Anti-Z (rabbit)  1250  69500 
Anti-Z (mouse)  330  4750 
Anti-AMEF (rabbit)  312  0§ 
Anti-AMEF (mouse)  300  0§ 
Normal seruml]  0  0 
Given amounts of either AMEF or normal ~-D-galactosidase were mixed with the indicated 
serum  in  order  to  test for activation or  precipitation respectively according to  procedure 
described  in  Materials  and  Methods. 
* EUof Z precipitated at equivalence by 1 #1 serum. 
:~ Increase in EU produced by 1 ml serum in AMEF excess. 
§ Not  different from  normal  serum. 
II Normal serum did not precipitate detectable amounts of enzyme. The activity of AMEF 
was not significantly enhanced. 
TABLE  II 
Suppression of Activating Antibody Response by Sensitization with AMEF 
Immunization (day 0)  Titer  (day 18)  Challenge  Titer (day 34) 
(day 18) 
Dose  Activ.  Precip.  Dose  Activ.  Precip. 
1  Freund's adjuvant  0.4  n.t.  none  2  0 
2  Freund's adjuvant  n.t.  n.t.  12 pg Z  129  128 
3  15 #g AMEF  0  32  12 #g Z  0  512 
4  12 #g Z  99*  n.t.  12 pg Z  137  512 
Mice were preimmunized according to  the above schedule and tested for production of 
precipitating and activating antibodies. The titers are expressed in the same units used in 
Table I.  Groups were composed of three animals, except for No.  3 which had six mice. Al! 
antigens were  injected intraperitoneally in  Freund's adjuvant.  Activ.,  activating;  Precip., 
precipitating; n.t., not tested. 
*This group was  tested on the 12th day. 
Comparison Between the Immunogenicity of AMEF  and Z  Studied by Adoptive 
Transfer.--The  suppressive  effect  of  preimmunization  with  AMEF  was  sub- 
jected  to  a  more  stringent  test  by  studying  it  during  adoptive  transfer,  thus 
reducing the  presence  of  preformed  circulating  antibodies  or  cell-bound  anti- 
bodies. Suspensions of normal spleen cells, AMEF-immunized  spleen cells,  and CELADA,  ELLIS~  BODLUND,  AND  ROTMAN  757 
a  1:1  mixture of the  two were  each  transferred to irradiated syngeneic  mice. 
Immediately after the transfer, the animals were divided into two  groups and 
each of them was  challenged with an injection of 10 ~ug of Z/mouse,  in either 
soluble form  or  mixed  with  Freund's  adjuvant.  This  type  of  challenge  was 
chosen in order to discriminate between  a  primary and a  secondary  response, 
since several cases are known  in which  small doses of soluble protein  antigen 
fail to elicit a  primary adoptive response in the mouse while effectively stimu- 
lating a secondary response (21, 22). After the transfer, the recipient mice were 
bled at weekly intervals and the sera were titrated for activating and  precipi- 
TABLE III 
Comparison Between Adoptive Response of AMEF-Sensitized and Naive Spleen Cells 
Group 
No. 
Pre-  of cells  Challenge 
treatment  transferred  with Z 
of donors  (X I07) 
Titer 
day 7  day 14  day 22  day 28 
•  d  ~  d  .  ~  ~ 
1  AMEF  3  Soluble  0  0  0  0  150  36  140  76 
2  AMEF  3  Freund's  0  20  0  40  264  200  153  290 
3  AMEF  115-;5j  mix  Soluble  0  0  0  0  52  16  32  20 
None  l 
4  AMEF  115-;5) mix  Freund's  0  5  0  20  104  70  96  145 
None  1 
5  None  3  Soluble  0  0  0  0  0  0  0  5 
6  None  3  Freund's  0  0  0  0  121  28  310  70 
The indicated numbers of spleen cells from either AMEF-primed donors, normal donors, 
or a  mixture of  the two  types, were  transferred to groups  of X-irradiated recipients and 
challenged  with 100  #g Z in soluble form  or in Freund's adjuvant. Activating (Act.)  and 
precipitating (Prec.)  titers were  determined in the serum  at weekly intervals and are ex- 
pressed in the same units used in Table I. 
tating  antibodies. The  results  of  this  experiment  (Table  III)  show  that  the 
transfer  of cells from  animals immunized with AMEF, in  contrast  to normal 
cells, produced a  secondary response with respect to both activating  and pre- 
cipitating antibodies after challenge with  soluble Z  (compare  groups  1  and  5 
of Table  III)  and  that  the  response  was  proportional  to  the  number  of  the 
sensitized cells injected (see group 3). The difference between  the challenge with 
soluble Z  and with Z in Freund's adjuvant indicates that,  similar to other pro- 
teins, fl-D-galactosidase in the soluble form and  in the dose range tested fails to 
elicit a  primary response in an adoptive transfer system. 
The susceptibility of cells from mice preimmunized with Z  to the  challenge 
by AMEF  in an adoptive transfer was also examined. The results (Table IV) 
show that AMEF  can elicit a  secondary response for both activating and pre- 758  ANTIBODY  ACTIVATION  OF  DEFECTIVE  ENZYME 
TABLE  IV 
Adoptive Response of Spleen  Cells from Mice Preimmunized with Z and 
Challenged with Z and AMEF 
Titer 
Group  Type of challenge  day 7  day  14  day 19  day 25 
Act.  Prec.  Act.  Prec.  Act.  Prec.  Act.  Prec. 
1  No challenge*  0.28  0.18  328  n.t.  48  40  101  n.t. 
2  10 #g Z  1280  4.5  5040  n.t.  4570  330  2140  n.t. 
3  10 #g AMEF  290  2.0  850  n.t.  704  330  720  n.t. 
2  X  l0  T Spleen cells from donors preimmunized with Z  were  transferred  to  three groups 
of X-irradiated  mice which were,  respectively:  not challenged, injected with Z, and injected 
with  AMEF.  The  response in activating and  precipitating  antibodies  during 25  days after 
transfer was followed. The units are the same as those used in Table I. Act., activating; Prec., 
precipitating;  n.t., not tested. 
* Residual primary response. 
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Fro. 2.  Double reciprocal  plot  of enzyme activity as a  function of AMEF  concentration 
in the presence of a  fixed concentration of anti-Z serum and various concentrations of anti- 
AMEF  serum. Triangles:  1700 precipitating units  (P.U.)  of anti-Z  (1  P.U.  is defined as the 
amount of serum necessary to  precipitate  1  EU  of Z,  taking 50%  precipitation  as the end 
point). Crosses (X):  1700 P.U. of anti-Z plus 250 P.U. of anti-AMEF. Open circles: 1700 P.U. 
of anti-Z plus 500  P.U.  of anti-AMEF. Squares:  1700 P.U.  of anti-Z plus 750  P.U.  of anti- 
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cipitating antibodies, although this was considerably smaller than that caused 
by Z. 
Competition Between Anti-AMEF and Activating Antibodies.--Although anti- 
AMEF sera did not activate AMEF, they could still contain specific antibodies 
capable  of  competing with  the  activating  antibodies  present  in  anti-Z  sera. 
This possibility was tested by mixing anti-AMEF and anti-Z sera in different 
proportions and  then assaying each mixture for its  ability to activate serial 
concentrations of AMEF ranging from 10  -6 to 3)<  10  -8 M. The results can be 
conveniently expressed in a double reciprocal plot of 1/EU against  1/[AMEF]. 
In Fig.  2 it is shown that under conditions of limiting AMEF  concentration 
(points on the right side of the graph),  mixing  1,  2,  or 3 vol of anti-AMEF 
serum with a given amount of anti-Z serum resulted in progressively less enzy- 
matic activity. In contrast, in excess of AMEF  (points near the ordinate) no 
significant inhibition was seen. The family of rectilinear curves obtained ex- 
trapolated to the same value on the ordinate as expected if competitive inhibi- 
tion was involved. 
DISCUSSION 
The results presented above show that AMEF and Z, two large polypeptides 
coded by a mutant and the normal allele of the #-D-galactoside gene of Escher- 
ichia coli, respectively, differ in their immunogenicity since only the latter can 
stimulate  the production of antibodies capable of activating AMEF. On the 
other hand, the tests for cross-reactivity indicated no differences in the capacity 
to absorb  antibodies directed against  either of them. Assuming  that  a  given 
site of the /3-D-galactosidase  molecule is  endowed with both immunogenicity 
and antigenicity with regard to activating antibodies, it would follow that the 
determinant of Z responsible for eliciting the production of activating antibodies 
is also present in AMEF but in a somewhat altered conformation. This assump- 
tion is consistent with two lines of evidence, namely, (a) genetic data indicating 
that the difference in primary structure between AMEF and Z resides in one 
amino acid substitution (17), and (b) the binding of a single molecule of anti- 
body or of FaD is enough to increase the activity of AMEF  (18)3 Under  this 
hypothesis, one would expect that  the altered determinant  in AMEF  would 
elicit antibodies which could bind AMEF but could not activate it. The fact 
that  anti-AMEF  serum  competes with  anti-Z  serum  for activation (Fig.  2) 
supports this idea. 
The suppressive effect on production of activating antibodies caused by pri- 
mary immunization with AMEF resembles that found in certain hapten -carrier 
experiments in which primary immunization with a given hapten-carrier mole- 
cule prevented an antibody response to a cross-reacting hapten when the latter 
was used as immunogen on the same carrier (24). This effect has been explained 
by the model of the "original antigenic sin," which postulates that a secondary 76O  ANTIBODY  ACTIVATION  OF  DEFECTIVE  ENZYME 
immunization with a cross-reacting determinant serves to stimulate a cell pop- 
ulation which had been previously enlarged by injection of the original immuno- 
gen instead of reacting with naive specific antigen-sensitive cells. According to 
this theory, if one considers only the immunogenic determinant responsible for 
the synthesis of activating antibodies,  our results  could be explained by the 
priinary injection of AMEF producing an increase in  the population of cells 
which  synthesizes  nonactivating  antibodies  against  the  determinant.  Upon 
subsequent  exposure to the cross-reacting determinant of Z  these cells would 
heighten their production of nonactivating antibodies. However, this would be 
an oversimplification since the results of our adoptive transfer experiments show 
the presence of antigen-sensitive cells specific for activating antibodies in ani- 
mals which exhibited a suppressed response to Z. Thus, the suppression effect 
of AMEF sensitization could be attributed to both circulating antibodies and 
memory cells competing with naive antigen-sensitive cells for the newly injected 
Z. In addition, since the anti-AMEF antibodies can compete with activating 
antibodies for AMEF, the presence of small proportions of activating antibodies 
in the serum of animals exhibiting AMEF-mediated suppression would tend to 
be undetectable. From these considerations, one would predict that immuno- 
genic blanketing between determinants  which  are  closely related will be fre- 
quently found among sets of complex macromolecules differing in the make-up 
of one determinant while identical for many others. In order to test this pre- 
diction, it would be expedient to search for more pairs of macromolecules such 
as AMEF and Z  in which a  single determinant can be specifically and easily 
assayed. 
According  to  an  alternative model,  a  given  class  of antigen-sensitive cells 
would be  potential  responders  to both Z  and AMEF.  The first of these two 
molecules to come in contact with the cell would determine the final three-di- 
mensional configuration (in terms of ability to activate) of the antibody deter- 
minant produced by the cell. This idea agrees with the framework of theories 
on  antibody formation which  postulates  that  oligopotent  cell  precursors  of 
antibody-forming cells have information for several amino acid sequences: for 
example, a discrete number of the corresponding DNA  segments would be  in- 
serted in the gene coding for the variable region of the immunoglobulin chains. 
During the induction phase the antigen may play a role in this choice, thereby 
modulating the binding characteristics of the antibody that the cell clone will 
eventually produce (25). 
If anti-AMEF antibodies bind AMEF at the same site as anti-Z-activating 
antibodies, a  molecular mechanism is needed to explain why the anti-AMEF 
sera fail to elicit the ~-galactosidase function of AMEF. A plausible explanation 
is illustrated in Fig. 3, using a key-keyhole symbolism. The square, round, or 
triangular figures represent the position of binding forces within the antigenic 
determinant;  we shall call them here a,  b,  and c in their protruded form and CELADA,  ELLIS,  BODLUND,  AND  ROTMAN  761 
a,  i3,  and  3"  in  their  invaginated  one,  respectively.  Choosing  this  number  of 
sub-sites  is  arbitrary.  In  fact,  the  combining  region  of  antibodies  directed 
FIG. 3.  A  model  consistent with our  findings on immunogenicity and antigenicity of  Z 
and AMEF and on AMEF activation. The units represent determinants in either Z, AMEF, 
or the respective antibodies using key-keyhole nomenclature to indicate chemical groups in 
each determinant. Units with invaginations represent antibody determinants, and those with 
protrusions, antigen determinants. 
Fig. 3  A:  Immunogenicity. The difference in conformation between Z and AMEF is sym- 
bolized by the displacement of one of the groups  (the triangular-shaped group on the right 
side).  As a  consequence, Z  and AMEF  elicit different antibodies  (dark  cross=hatdhed area) 
directed against the site in question. 
Fig.  3  B:  Cross-reaction. AMEF,  Z, anti-AMEF, and anti-Z antibodies fully cross-react 
in all combinations due to the presence of at least two groups in common. AMEF competes 
with Z for anti-Z antibodies. 
Fig.  3  C:  Activation of  AMEF.  Alternative model  1:  AMEF  exists in two  forms,  one 
enzymatically active, the other inactive, which are in equilibrium with a constant Ki' favoring 
the inactive form. The presence of activating antibodies displaces the equilibrium t0 the right 
by binding preferentially to the active form  (with three dots)  in a  reaction with K3  as con- 
stant.  Alternative model  2:  AMEF  exists as a  single molecular species.  The activation by 
antibodies proceeds  in  two steps  with K2  and  K4  as constants,  respectively.  An allosteric 
reaction  of  AMEF  with  activating antibodies causes  a  conformational change  in  AMEF 
resulting in a  three-dimensional structure similar to Z. The anti-AMEF antibody does ~not 
lead to this allosteric change. 
against  "sequential"  determinants  of  polypeptide  nature  has  been  recently 
shown  to  accommodate  up  to four  amino  acid  residues  (28),  while  a  !!confor- 
mation-dependent"  determinant  may  involve  many  more  stetidally  related 762  ANTIBODY  ACTIVATION  OF  DEFECTIVE  ENZYME 
residues (23). Both circulating antibodies and cellular receptors  specific for Z 
would  have  determinants  with  o~-13-'y components,  while  their  counterparts 
specific for AMEF would only have a-~. The antigens would both have all the 
a-b-c components except that, in AMEF, one of them, c, would be altered but 
capable of undergoing a conformational change so as to resemble the normal c. 
The model accounts for our results by postulating that a determinant with 
only a-b has a  low but finite probability of stimulating a  cell with an o~-/3-~, 
receptor while still capable of absorbing completely humoral o~-j3-~, antibodies. 
Thus, the a-b  determinant could elicit o~-3 antibodies  efficiently but only re- 
duced amounts of a-fl-'y antibodies. Cross-reactions between the a-b and a-b-c 
antigens would be complete with either o~-fl or o~-13-'y antibodies (Fig.  3A  and 
B). According to the model, the activation of AMEF is a  protein-to-protein 
allosteric reaction directed by anti-Z antibodies with ~-13-~ configuration. Two 
plausible mechanisms for this reaction are illustrated in Fig. 3C. According to 
one of them,  in  the  AMEF,  there is  an  equilibrium  between  enzymatically 
active and inactive molecules with an equilibrium constant K1 favoring largely 
the inactive form. The activating antibodies would bind preferentially to the 
active form and therefore would displace the equilibrium towards  the  active 
form. According to the second mechanism, the activating antibodies react with 
a single molecular species of AMEF and cause the conformational change lead- 
ing to an increase in enzymatic activity (bottom part of Fig. 3C).  The ~, com- 
ponent of the antibody would be required in the activation reaction in order 
to produce an induced fit. Considering the fact that AMEF is more negatively 
charged than Z, one could visualize 7 as a charged group which would neutralize 
the negative component of the AMEF determinant. This idea is supported by 
the finding of two types of antibodies which differ both in their electrical charge 
and in  the  ability  to activate different genetically altered ~-D-galactosidases 
(26). 
The postulate that the activation of AMEF  occurs through an allosteric re- 
action is consistent with  the observations that the E. coli  mutants  containing 
altered/3-I)-galactosidases activable by anti-Z serum map throughout the genetic 
region determining the structure  of the enzyme (12,  17, 27), since it rules out 
the possibility that the catalytic site of the enzyme is directly involved. 
SUMMARY 
Two closely related protein antigens were used to study immunogenic com- 
petition. Namely, normal ~3-D-galactosidase of Escherichia coli (Z) and a geneti- 
cally defective/3-D-galactosidase (AMEF) which seems to differ from the normal 
in one amino acid substitution. A unique characteristic of this pair of antigens 
is that, although they are indistinguishable in precipitation and absorption tests 
with  antibodies,  the  enzymatic  activity  of  AMEF  is  specifically increased 
several-hundredfold in the presence of antibodies directed against Z. The fol- CELADA, ELLIS, BODLUND, AND  ROTMAN  763 
lowing results show that Z and AMEF also differ in their immunogenic ability: 
(a) antibodies directed against Z activated AMEF; antibodies directed against 
AMEF did not activate, but competed specifically with activating antibodies. 
(b)  Animals immunized with AMEF  failed to  produce  activating  antibodies 
when they were subsequently challenged with Z, although the presence of some 
cells primed to produce activating antibodies could be demonstrated by adop- 
tive transfer.  (c)  Animals preimmunized with Z  were stimulated in  their pro- 
duction of activating antibodies by AMEF challenge, although not as efficiently 
as with Z. 
A  model explaining these observations by competition for the immunogenic 
site among antigen-sensitive cells carrying cross-reacting receptors is presented. 
We are  grateful to Birgitta  Asj~, Rosario Guzman, and  Anna H~gberg for their  able 
technical assistance. 
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